Trials / Recruiting
RecruitingNCT05787561
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avutometinib (VS-6766) | 3.2 mg PO, twice weekly |
| DRUG | Defactinib | 200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle. |
Timeline
- Start date
- 2023-03-15
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2023-03-28
- Last updated
- 2026-03-12
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05787561. Inclusion in this directory is not an endorsement.